Physiological Research Pre-Press Article

Increased gene expression and production of spinal

cyclooxygenase 1 and 2 during experimental osteoarthritis pain

Michaela Procházková¹, Peter Zanvit², Tomáš Doležal¹,

Ludmila Prokešová², Miloslav Kršiak¹

¹ Department of Pharmacology, Third Faculty of Medicine, Charles University

in Prague, Czech Republic

² Institute of Immunology and Microbiology, First Faculty of Medicine, Charles University in Prague, Czech Republic

Corresponding author: Michaela Procházková

Department of Pharmacology,

Third Faculty of Medicine,

Charles University in Prague,

Ruská 87,

Prague, 100 34

Czech Republic

tel. +420 2 67 102 450

fax. +420 2 67 102 461

e-mail: michaela.prochazkova@lf3.cuni.cz

Short title: Expression and production of COX-1,2 during osteoarthritis

Summary

Knowledge of involvement of spinal COX-1 and COX-2 in pain due to osteoarthritis could be useful for better understanding of its pathogenesis and therapy. In this study, therefore, we have investigated a long-term pattern of expression and production of spinal COX-1 and COX-2 in the model of osteoarthritis induced in rats by injection of monoiodoacetate (MIA) into the knee joint.

MIA injection produced thermal hyperalgesia (assessed by the plantar test) and tactile allodynia (measured with von Frey hairs). The pain measures reached maximum on the 5th day, then remained relatively stable.

The expression of spinal COX-2 mRNA reached maximum on the 5th day (5.2 times; P<0.001) and remained increased until the 31th day (4.9 times; P<0.001). Expression of spinal COX-1 mRNA increased gradually reaching maximum on the day 31 (4.5 times; P<0.001) when the relative expression of both genes was almost equal. The production of both proteins was almost similar at the beginning of the experiment. The highest production of COX-2 protein was observed on day 5 after induction of osteoarthritis (increased 3.9 times). The levels of COX-1 protein increased gradually with maximum on day 31 (3.4 times).

The present findings indicate that not only expression of COX-2 mRNA but also that of COX-1 mRNA is significantly increased in the spine during osteoarthritis pain. Thus, in contrast to inflammatory pain, the upregulation of spinal COX-1 may be important in osteorthritis pain.

Keywords: osteoarthritis, cyclooxygenase (COX), pain, spinal cord

Introduction

Cyclooxygenases are the enzymes that catalyze the conversion of arachidonic acid to prostaglandins which play an important role in inflammation and pain. There are two identified cyclooxygenase (COX) isoenzymes: COX-1 and COX-2. COX-1 is the "housekeeping" form, expressed by a wide variety of cells. COX-2 is highly inducible in response to inflammatory and noxious stimuli. Both cyclooxygenases are constitutively expressed in the spinal cord (Kaufmann *et al.* 1997).

The involvement of spinal COX-1 and COX-2 in various pain states is not fully understood. COX-2 gene expression and production in the spinal cord was significantly increased in rats in the model of peripheral inflammation induced by intraplantar injection of Freund's complete adjutant (Beiche *et al.* 1996, Hay *et al.* 1997, Beiche *et al.* 1998). No increase of COX-1 gene expression and production in the spinal cord was found in this model which was associated with swelling, hyperalgesia and allodynia (Beiche *et al.* 1996, Hay *et al.* 1997, Beiche *et al.* 1998). In agreement with these findings, spinal COX-2 mRNA were markedly increased and spinal levels of COX-1 mRNA were not significantly altered in peripheral inflammation induced by intraplantar injection of carrageenan (Procházková *et al.* 2006).

Rats with streptozotocin-induced diabetes exhibited significantly increased levels of spinal COX-2 protein and activity, along with hyperalgesia (Ramos *et al.* 2007). Intrathecal administration of COX-2 inhibitors has an anti-hyperalgesic effect on streptozotocin-induced mechanical hyperalgesia (Matsunaga *et al.* 2007). A sharp upregulation of spinal COX-2 was reported in the mouse model of amyotrophic lateral sclerosis (McGeer and McGeer 2002).

On the other hand the expression of COX-2 mRNA in the spine was less dominant in postoperative pain model than in inflammatory pain while expression of spinal COX-1 mRNA was significantly increased in postoperative pain (Procházková *et al.* 2006). The important role of COX-1 in the model of postoperative pain was also shown by Zhu (Zhu *et al.* 2003).

Spinal COX-1 appears to play role also in the model of neuropathic pain. Spinal COX-1 expression was increased after partial peripheral nerve transsection (Zhu and Eisenach 2003). The inhibition of COX-1 prevented the development of allodynia and hyperalgesia after peripheral nerve ligation (Hefferan *et al.* 2003).

One of the widespread painful disorders is osteoarthritis (OA). OA is a degenerative joint disease. The joints are characterized by a progressive degeneration of articular cartilage leading to inflammation and pain. In an attempt to peruse the patophysiology of osteoarthritis, experimental models that mimic human disease have been developed (Pritzker 1994).

One of the most frequently used and one of the best characterized models of osteoarthritis is that of monoiodoacetate (MIA) induced OA. This model was first described twenty years ago by Kalbhen (Kalbhen 1987). Monoiodoacetate inhibits the activity of glyceraldehyde-3-phosphate dehydrogenase in chondrocytes and producing degeneration of the cartilage.

Knowledge of involvement of spinal COX-1 and COX-2 in pain due to OA could be useful both for better understanding of its pathogenesis and for its therapy. In this study, therefore, we have investigated a long-term pattern of expression and production of spinal COX-1 and COX-2 in the model of monoiodoacetate induced

osteoarthritis. In particular we have attempted to correlate changes in spinal cord production of COX-1 and COX-2 and expression of mRNA for COX-1 and COX-2 with the development of thermal hyperalgesia and tactile allodynia.

Methods

Animals

Male Wistar albino rats (weight 200-220 g) obtained from VÚFB Konárovice (Czech Republic) were used in all experiments. The animals were housed under standard laboratory conditions (in a temperature-controlled (21±1°C) room with a normal 12-h light/dark cycle). Animals were fed standard rat chow (Pelet, St1; VELAZ, Czech Republic) with water ad libitum throughout the whole experiment. Rats were acclimated to their surroundings over 1 week to eliminate the effect of stress before the experiment.

All experiments were reviewed and approved by the Comittee for Protection of Laboratory Animals of the Third Faculty of Medicine at Charles University and were concordant with IASP Committee for Research and Ethical Issues requirements (Zimmermann 1983).

Induction of osteoarthritis

For induction of osteoarthritis, rats were anaesthetized with halothane (Narcotan, Zentiva). Eight rats per group received single injection of monoiodoacetate (2 mg) (Sigma–Aldrich) into the right knee joint in a total volume of 25 μ l. Control animals (n=8) were injected 25 μ l of vehicle into the right knee joint under the same conditions.

Paw withdrawal testing

The response to noxious thermal stimulus was determined using thermal plantar device (Ugo Basile, Italy) according to the procedure described by Hargreaves (Hargreaves *et al.* 1988) before and in defined times during 31 days after injection of monoiodoacetate. Rats were placed to opaque plastic chambers (22 cm in width x 17 cm in lenght x 14 cm in height) for 10 minutes prior to the start of the each experiment. This lets the animals accomodate to their new environment before testing. Movable infrared radiant heat source was placed directly under the plantar surface of the hind paw and the time taken for hind paw withdrawal was monitored. A cut-off time of 20 seconds was used in all experiments. Three tests were carried out at 10 minutes intervals and then the mean value taken as the nociceptive treshold.

Following three baseline measurements, rats received intraarticular injection of monoiodoacetate or saline. In the defined times after injection of monoiodoacetate or saline, paw withdrawal latencies were recorded.

von Frey hairs

Tactile allodynia was measured with von Frey hairs (Ugo Basile, Italy). Animals were placed into wire mesh bottom cages and allowed to aclimatise prior the start of the experiment. Tactile allodynia was tested by touching the plantar surface of the animal's hind paw with von Frey hairs in ascending order of force until a paw withdrawal response was elicited. Each von Frey hair was applied to the paw for 5 seconds or until a response occurred. Once a withdrawal response was established, the paw was retested. The lowest amount of force required to elicit a response was recorded as withdrawal threshold in grams.

Following three baseline measurements, rats received intraarticular injection of monoiodoacetate or saline. Paw withdrawal thresholds were measured in defined times after injection of monoiodoacetate or saline.

Tissue preparation

In four different times post monoiodoacetate or saline injection, animals (eight per group) were euthanized in halothane anaesthesia. Lumbar section of the spinal cord was ejected and given in RNAlater solution (Qiagen).

RNA isolation

Disruption and homogenization of small parts of the lumbar section of spinal cord weighing approximately 100 mg stabilized with the RNAlater (Qiagen) was performed using Ultra-Turrax (Ika). Total RNA was isolated with the RNeasy lipid tissue isolation kit (Qiagen) according to the manufacturer's instruction. RNA integrity was determined by gel electrophoresis in 2 % agarose gel stained with ethidium bromide. The purity of the RNA was assessed by the ratio of absorbance at 260 nm and 280 nm. RNA was stored in aliquots at -70 °C until used for reverse transcription.

Reverse transcription

RNA samples were reverse transcribed using RT buffer, 25mM MgCl2, 10mM dNTPs (2,5 mM of each), 50 μ M random hexamers, RNase inhibitor (20 U/ μ l) and reverse transcriptase (50 U/ μ l), all from Applied Biosystems. The mix was aliquoted into individual tubes and RNA was added. Samples were incubated for 10 minutes at 25 °C, 30 minutes at 48 °C and then for 5 minutes at 95 °C.

Real-time PCR

A reaction mix for real-time PCR was made with TaqMan Universal PCR master mix, water and Assays on Demand gene expression products (all Applied Biosystems). Reaction mix was aliquoted to the wells on a real-time PCR plate. Each sample was made in duplicate. A volume of 5 µl of cDNA was added to each well. A no-template control contained instead cDNA water. PCR reaction was run on an ABI PRISM 7000 (ABI PRISM 7000 SDS analytical cycler, Appiled Biosystems) using standard conditions.

Expression of COX-1 and COX-2 was normalized to RNA loading for each sample using the beta2 microglobulin as an internal standard. The quantity of mRNA was given as 2- $\Delta\Delta$ ct. $\Delta\Delta$ ct was calculated as follows: $\Delta\Delta$ ct= Δ ct (gene of interest) – Δ ct (endogenous control).

ELISA

For detection of antigens, sandwich enzyme-linked immunosorbent assay (ELISA) was used. Microtiter NUNC plates (Schoeller) were coated with monoclonal antibody specific for cyclooxygenase 1 (Alpha Diagnostic) and for cyclooxygenase 2 (Kamiya Biomedical Company) diluted in coating buffer and incubated overnight.

After 24 hours the plates were washed two times with washing buffer PBS (phosphate buffered saline) and two times with PBST (PBS containing 0,05% Tween 20, Sigma-Aldrich). Each well was then filled with PBST and incubated for 1 hour at room temperature to prevent non-specific adsorption of protein to the well surfaces. In course of this time, samples from spinal cord from monoiodoacetate injected or control animals were homogenized in 5% FBS (fetal bovine serum, Sigma-Aldrich) and then added to the wells. Two hours after this incubation at room temperature, the plates were washed two

times with PBS and two times with PBST (PBS containing 0,05% Tween 20, Sigma-Aldrich).

The secondary biotinylated antibodies (Acris Antibodies) were added to the wells and incubated for next 2 hours. The plates were then washed, followed by incubation of 1:1000 dilution of streptavidin (Beckman Coulter) for 20 minutes. After washing the coated well, TMB (tetramethylbenzidine, Sigma-Aldrich) and citric buffer with peroxide were added.

For development of the colour reaction the plates were incubated in the dark and the reaction was stopped by the addition of H2SO4 to each well. The colour intensity was determined at 450 nm on Multiscan RC reader. Results are expressed as stimulation index (OD of monoiodoacetate treated vs. OD of control animals) as mean values \pm S.E.M.

Drugs

Monoiodoacetate was purchased from Sigma-Aldrich and halothane (Narcotan) was obtained from Zentiva.

Statistical analysis

All results are expressed as mean values \pm S.E.M.(standard error of mean). Statistical analysis was carried out using two-way repeated measures ANOVA with a post-hoc Student-Newman-Keuls test in case of repetitive testing of paw withdrawal. P<0.05 was accepted as significant.The evaluation of real-time PCR data was done by one-way ANOVA with a post-hoc Tukey's test using 2- $\Delta\Delta$ ct values of each samples. A value of P<0.05 was considered significant. Data from ELISA method are presented as stimulation index (OD of monoiodoacetate treated vs. OD of control animals) as mean values \pm S.E.M. and were analyzed using unpaired t-test. The results were considered significant if the P value was less than 0.05.

Results

Effect of monoiodoacetate on paw withdrawal latency

Paw withdrawal latencies were measured before and in defined times after aplication of monoiodoacetate or saline. Intraarticular injection of monoiodoacetate into the right knee joint produced marked and significant reduction of paw withdrawal latencies to noxious radiant heat stimuli. Decreased paw withdrawal latencies were evident from the first day following injection of monoiodoacetate, with the maximum on the 5th day after induction of osteoarthritis (statistically significant at all observed times compared to baseline and to control animals; P<0.001). The paw withdrawal latencies remained decreased until 31st day (Fig. 1).

Effect of monoiodoacetate on tactile allodynia

Tactile allodynia was measured with von Frey hairs before and following intraarticular injection of monoiodoacetate or saline. The injection of monoiodoacetate into the right knee joint induced marked allodynia. The onset of allodynia was evident from the first day following injection of monoiodoacetate. Fig. 2 shows that tactile allodynia in the monoiodoacetate injected knee joints reaches the maximum at day 5 and was observed throughout all the time of the experiment (statistically signifiant at all observed times compared to baseline and to control animals, P<0.001).

Expression of COX-1 and COX-2 mRNA in the spinal cord after induction of osteoarthritis

Expression of COX isoenzymes was measured in 4 different times. First day after monoiodoacetate injection, spinal levels of COX-1 mRNA and COX-2 mRNA were moderately increased (2.3 and 2.6 times, respectively; P<0.05). The expression of spinal COX-2 mRNA was much higher on the day 5 (5.2 times; P<0.001) and remained increased at this level until the day 31 (4.9 times; P<0.001). On the other hand, expression of spinal COX-1 mRNA increased gradually during the whole testing period reaching maximum on the day 31 (4.5 times; P<0.001) when the relative expression of both genes was almost equal. All results are expressed in comparison with control animals (Fig.3).

Production of COX-1 and COX-2 proteins after induction of osteoarthritis

The production of spinal COX proteins was comparable to the expression results. The production of COX-1 and COX-2 proteins was almost similar at the beginning of the experiment (1.9 and 2.0 times, respectively; P<0.001). The highest production of COX-2 protein was observed on day 5 after induction of osteoarthritis (increased 3.9 times; P<0.001). The levels of COX-1 protein increased gradually from the 5th day after induction of osteoarthritis (1.7 times; P<0.001) with maximum on day 31 (3.4 times; P<0.001). Results are expressed as stimulation index (OD of monoiodoacetate treated vs. OD of control animals) as mean values \pm S.E.M. (Fig.4).

Discussion

MIA injection produced pain as measured by von Frey thresholds and paw withdraval latencies in the plantar test. The pain measures reached maximum on the 5th day, then remained relatively stable. Expression and production of spinal COX-2 was rapidly increased paralell to pain measures reaching maximum on the 5th day and then remained relatively stable. On the other hand the expression and production of spinal COX-1 mRNA increased at a slower pace but 31 days after induction of osteoarthritis there was almost no difference between relative amount of COX-1 and COX-2 mRNA.

The present results indicate that osteoarthritis pain has different patterns of expression of spinal mRNA for COX-1 and COX-2 compared with chronic inflammatory or postoperative pain. Expression and production of spinal COX-2 were significantly increased 22 days after induction of arthritis by CFA while spinal COX-1 mRNA and protein levels remained unchanged at this time (Beiche *et al.* 1996, Beiche *et al.* 1998). In contrast, COX-1 might play more important role in postoperative pain. Expression of spinal COX-1 mRNA raised gradually after paw incision in the rat and 6 hours after the surgery, there was no diference between relative amount of COX-1 and COX-2 mRNA in the spinal cord (Procházková *et al.* 2006).

The increased expression and production of spinal COX-1 in some types of pain may have therapeutic implications. The lack of analgesic effect of intrathecally administered selective inhibitor of COX-2 (NS-398) in the model of postoperative pain induced by skin incision suggest that spinal COX-2 might play less important role in this type of pain (Yamamoto and Sakashita 1999). Intrathecal administration of COX-1 inhibitors, but not of COX-2 inhibitor, dose dependently reduced pain in the model of postoperative pain (Zhu *et al.* 2003). Perioperative intrathecal administration of COX-1 inhibitors (COX-1 preferring inhibitor ketorolac and COX-1 selective inhibitor SC-560), but not of selective COX-2 inhibitor (NS-398), reduced paw incision induced hypersensitivy in the model of postoperative pain in rats (Zhu *et al.* 2005). Intrathecal administration of selective COX-1 inhibitor (SC-560), but not selective inhibitor of COX-2 (NS-398), restores normal exploratory activity (rearing behaviour) after laparotomy (Martin *et al.* 2006).

The increased expression of spinal COX-1 mRNA found in the present study corroborates other findings suggesting important role of this enzyme in osteoarthritis. Knorth and colleagues demostrated the important role of synovial COX-1 in patients with primary osteoarthritis (Knorth *et al.* 2004).

The expression of COX-1 and COX-2 mRNA from synovial tissue from patients with osteoarthrisis or from patients with inflammatory arthritis (rheumatoid arthritis) was compared by Siegle (Siegle *et al.* 1998). The expression of COX-2 was found to be elevated in both groups of the patients, but the difference in expression of both cyclooxygenases were much more evident in the group of patients with rheumatoid arthritis. The amount of COX-2 mRNA was significantly higher in patients with rheumatoid arthritis compared with patients with osteoarthritis.

The expression of both, COX-1 and COX-2 mRNA, was detected in cells from synovial fluid of patiens with acute and chronic arthritis. COX-1 was the most abundant isoform with the strong immunostaining observed in a special fraction of mononuclear cells (Iniguez *et al.* 1998).

In summary, the present findings indicate that not only expression and production of COX-2 but also that of COX-1 is significantly increased in the spine in osteoarthritis pain. In contrast to inflammatory pain, the increased expression and production of spinal COX-1 might play an important role in osteorthritis pain.

Acknowledgements

This work was supported by research grants VZ MSM0021620816 and IGA NR/9072-3.

Reference List

BEICHE F, SCHEUERER S, BRUNE K, GEISSLINGER G, GOPPELT-STRUEBE M: Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation. *FEBS Lett* **390**: 165-169, 1996.

BEICHE F, BRUNE K, GEISSLINGER G, GOPPELT-STRUEBE M: Expression of cyclooxygenase isoforms in the rat spinal cord and their regulation during adjuvant-induced arthritis. *Inflamm Res* **47**: 482-487, 1998.

HARGREAVES K, DUBNER R, BROWN F, FLORES C, JORIS J: A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. *Pain* **32**: 77-88, 1988.

HAY CH, TREVETHICK MA, WHEELDON A, BOWERS JS, BELLEROCHE JS: The potential role of spinal cord cyclooxygenase-2 in development of Freund's complete adjuvant-induced changes in hyperalgesia and allodynia. *Neuroscience* **78**: 843-850, 1997.

HEFFERAN MP, O'RIELLY DD, LOOMIS CW: Inhibition of spinal prostaglandin synthesis early after L5/L6 nerve ligation prevents the development of prostaglandin-dependent and prostaglandin-independent allodynia in the rat. *Anesthesiology* **99**: 1180-1188, 2003.

INIGUEZ MA, PABLOS JL, CARREIRA PE, CABRE F, GOMEZ-REINO JJ: Detection of COX-1 and COX-2 isoforms in synovial fluid cells from inflammatory joint diseases. *Br J Rheumatol* **37**: 773-778, 1998.

KALBHEN DA: Chemical model of osteoarthritis - a pharmacological evaluation. *J Rheumatol* **14**: 130-131, 1987. KAUFMANN WE, ANDREASSON KL, ISAKSON PC, WORLEY PF: Cyclooxygenases and the central nervous system. *Prostaglandins* **54**: 601-624, 1997.

KNORTH H, DORFMULLER P, LEBERT R, SCHMIDT WE, WITTENBERG RH, HEUKAMP M, WIESE M, WILLBURGER RE: Participation of cyclooxygenase-1 in prostaglandin E2 release from synovitis tissue in primary osteoarthritis in vitro. *Osteoarthritis Cartilage* **12**: 658-666, 2004.

MARTIN TJ, BUECHLER NL, EISENACH JC: Intrathecal administration of a cyclooxygenase-1, but not a cyclooxygenase-2 inhibitor, reverses the effects of laparotomy on exploratory activity in rats. *Anesth Analg* **103**: 690-695, 2006.

MATSUNAGA A, KAWAMOTO M, SHIRAISHI S, YASUDA T, KAJIYAMA S, KURITA S, YUGE O: Intrathecally administered COX-2 but not COX-1 or COX-3 inhibitors attenuate streptozocin-induced mechanical hyperalgesia in rats. *Eur J Pharmacol* **554**: 12-17, 2007.

MCGEER PL, MCGEER EG: Inflammatory processes in amyotrophic lateral sclerosis. *Muscle & Nerve* **26**: 459-470, 2002.

PRITZKER KP: Animal models for osteoarthritis: processes, problems and prospects. *Ann Rheum Dis* **53**: 406-420, 1994.

PROCHÁZKOVÁ M, DOLEŽAL T, SLÍVA J, KRŠIAK M: Different patterns of spinal cyclooxygenase-1 and cyclooxygenase-2 mRNA expression in inflammatory and postoperative pain. *Basic Clin Pharmacol Toxicol* **99**: 173-177, 2006.

RAMOS KM, JIANG Y, SVENSSON CI, CALCUTT NA: Pathogenesis of spinally mediated hyperalgesia in diabetes. *Diabetes* **56**: 1569-1576, 2007.

SIEGLE I, KLEIN T, BACKMAN JT, SAAL JG, NUSING RM, FRITZ P: Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue: differential elevation of cyclooxygenase 2 in inflammatory joint diseases. *Arthritis Rheum* **41**: 122-129, 1998.

YAMAMOTO T, SAKASHITA Y: The role of the spinal opioid receptor like1 receptor, the NK-1 receptor, and cyclooxygenase-2 in maintaining postoperative pain in the rat. *Anesth Analg* **89**: 1203-1208, 1999.

ZHU X, CONKLIN D, EISENACH JC: Cyclooxygenase-1 in the spinal cord plays an important role in postoperative pain. *Pain* **104**: 15-23, 2003.

ZHU X, CONKLIN DR, EISENACH JC: Preoperative inhibition of cyclooxygenase-1 in the spinal cord reduces postoperative pain. *Anesth Analg* **100**: 1390-3, 2005.

ZHU X, EISENACH JC: Cyclooxygenase-1 in the spinal cord is altered after peripheral nerve injury. *Anesthesiology* **99**: 1175-1179, 2003.

ZIMMERMANN M. Ethical guidelines for investigations of experimental pain in conscious animals. *Pain* **16**: 109-110, 1983.

Legends to figures:

Fig. 1. Paw withdrawal latencies to a noxious radiant heat stimulus before and after induction of osteoarthritis. Osteoarthritis reduced paw withdrawal latencies in the right (monoiodoacetate injected) hind paws. Control animals exhibited no differencies in paw withdrawal latencies. Withdrawal latencies of the left (uninjected) paws of osteoarthritis rats did not differ from those of control. The data represent observations from 8 animals per group displayed as means \pm S.E.M. (P<0.001 at all observed times compared to baseline and to control animals).

Fig. 2. Paw withdrawal thresholds to von Frey hairs before and after induction of osteoarthritis. Paw withdrawal thresholds to von Frey hairs were significantly decreased from the first day after injection of monoiodoacetate into the right knee joint. Control and uninjected (left paws) were not altered during the whole testing period. Results are expressed as median force in grams \pm S.E.M. required to induce paw withdrawal in 8 animals per group (P<0.001 at all observed times compared to baseline and to control animals).

Fig. 3. Relative expression of cyclooxygeanse 1 and cyclooxygenase 2 in lumbar section of spinal cord 1, 5, 14 and 31 days after induction of osteoarthritis (induced by injection of monoiodoacetate) as determined by real-time PCR. Each column represents observations from 8 animals displaed as means \pm S.E.M. Asterisks indicate significant difference between monoiodoacetate injected and control animals at respective time-points (*P<0.05; **P<0.01 and ***P<0.001).

Fig. 4. Production of cyclooxygenase 1 and cyclooxygenase 2 proteins in lumbar section of spinal cord 1, 5, 14 and 31 days after induction of osteoarthritis (induced by injection of monoiodoacetate) as determined by ELISA method. Results are expressed as stimulation index (OD of monoiodoacetate treated vs. OD of control animals) as mean values \pm S.E.M. Asterisks indicate significant difference between production of COX proteins in MIA injected and production of COX proteins in control animals at 4 different times (***P<0.001).

Fig. 1



Fig. 2



Fig. 3



Fig. 4

